NFKB1 and Miyoshi myopathy: Studies demonstrate that cells exhibiting an MDR phenotype exhibit significantly enhanced responsiveness to chemotherapeutic agents (45% response rate) following treatment with MDR-reversing agents and membrane-active drugs, including calmodulin antagonists, calcium channel blockers, local anesthetics, and cyclosporine.[41] Given that NF-κB activation contributes to chemoresistance, pharmacological inhibition of NF-κB represents another critical therapeutic approach for overcoming chemotherapy resistance in MM.